May 11, 2020 / 11:46 AM / 24 days ago

BRIEF-MyoKardia Announces Primary, All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten

May 11 (Reuters) - MyoKardia Inc:

* MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

* MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

* MYOKARDIA INC - MAVACAMTEN WELL TOLERATED; SAFETY RESULTS COMPARABLE TO PLACEBO

* MYOKARDIA INC - U.S. REGULATORY SUBMISSION PLANNED FOR EARLY 2021

* MYOKARDIA INC - HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENTS IN NYHA CLASSIFICATION

* MYOKARDIA INC - 30-WEEK TREATMENT WITH MAVACAMTEN RESULTED IN A HIGHLY STATISTICALLY SIGNIFICANT OUTCOME RELATIVE TO PLACEBO

* MYOKARDIA INC - RESULTS FROM PHASE 3 EXPLORER-HCM CLINICAL TRIAL WILL BE SUBMITTED TO A FUTURE PROFESSIONAL MEETING IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below